BioLineRX
BLRX
31 hedge funds and large institutions have $436K invested in BioLineRX in 2024 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 10 closing their positions.
1,500% more call options, than puts
Call options by funds: $16K | Put options by funds: $1K
0% more funds holding
Funds holding: 31 → 31 (0)
0% less ownership
Funds ownership: 0.01% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
68% less capital invested
Capital invested by funds: $1.34M → $436K (-$908K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$372K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$25.5K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$21.2K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$13K |
| 5 |
WGC
Watts Gwilliam & Co
Gilbert,
Arizona
|
+$12.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$465K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$128K |
| 3 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$84.3K |
| 4 |
AI
Atria Investments
Charlotte,
North Carolina
|
-$71.8K |
| 5 |
Morgan Stanley
New York
|
-$43.7K |
BLRX Hedge Fund Activity: Q4 2024 in Review
31 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2024, worth a combined $436K — down 68% from $1.34M a quarter earlier.
Fund positioning in BLRX was balanced in Q4 2024: 10 funds opened new positions, 10 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $372K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $465K sold.
- 31 institutional investors held BioLineRX (BLRX) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $436K of BioLineRX stock for Q4 2024, down 68% quarter-over-quarter.
- 10 funds opened new BioLineRX positions in Q4 2024 and 10 closed out, a net change of 0 holders.
- The largest BioLineRX buyer in Q4 2024 was Highbridge Capital Management, an estimated $372K added.
- The largest BioLineRX seller in Q4 2024 was Alyeska Investment Group, an estimated $465K sold.
Based on aggregated 13F filings for Q4 2024.